title: [Palliative treatment of advanced gastric cancer from surgical point of view].
abstract: Data are available on two multicenter observational studies, the East German Gastric Cancer Study (EGGCS) '02 (surgical interventions only) and the German Gastric Cancer Study II (QCGC) from 2007 to 2009 (after inauguration of multimodal therapeutic concepts) with regard to palliative treatment of advanced gastric cancer. Through the first investigation period from January to December 2002 (EGGCS) overall 1139 patients with primary gastric cancer were registered and evaluated and then from 2007 to 2009 (QCGC) another 2897 patients were included. Comparing both time periods, there were no significant changes in the distribution of tumor sites and stages according to the Union Internationale Contre le Cancer (UICC) classification, in particular, there was no significant reduction of advanced tumor stages. From 2007 to 2009 in total 521 patients (18 %) received neoadjuvant therapy, 401 patients (13.9 %) out of the group with curative intention and 120 (4.1 %) out of the group of patients with palliative intention. The proportion of palliative patients who underwent chemotherapy (with neoadjuvant intention and/or postoperatively) was 32.5 % (n = 223). Thus, the rate of palliative treatment (rate of no R0 resection status 29.6 %, rate of patients who did not undergo surgical intervention at all 9.5 %) could be diminished from almost 40 % in 2002 to 24.5 % through the time period from 2007 to 2009. Taking all patients together (with curative and palliative intention) an increase of the 4-year survival probability from 40.0 % to 48.5 % was observed after inauguration of multimodal therapy. After a 5-year follow-up median survival time was 34 months during the investigation period from 2007 to 2009 considering all study subjects. Patients who had undergone palliative surgical interventions benefited from postoperative palliative chemotherapy; however, as expected this was of greater benefit to patients with resecting surgical interventions than those with non-resecting operations. Palliative tumor resection (even R2 resection status) should be part of a concept of multimodal palliative therapy in cases of acceptable perioperative risk.
authors.affiliation: AN-Institut für Qualitätssicherung in der Operativen Medizin, Otto-von-Guericke- Universität Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Deutschland, I.Gastinger@freenet.de.
authors.forename: I
authors.initials: I
authors.lastname: Gastinger
authors.forename: J
authors.initials: J
authors.lastname: Windisch
authors.forename: F
authors.initials: F
authors.lastname: Meyer
authors.forename: H
authors.initials: H
authors.lastname: Ptok
authors.forename: R
authors.initials: R
authors.lastname: Steinert
authors.forename: R
authors.initials: R
authors.lastname: Otto
authors.forename: C
authors.initials: C
authors.lastname: Bruns
authors.forename: H
authors.initials: H
authors.lastname: Lippert
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D005743:Gastrectomy; D005763:Gastroenterostomy; D005773:Gastroscopy; D017052:Hospital Mortality; D006801:Humans; D007582:Jejunostomy; D053208:Kaplan-Meier Estimate; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods*; D011446:Prospective Studies; D012086:Reoperation; D015607:Stents; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016019:Survival Analysis